Otsuka Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising humanized monoclonal antibody targeting syndecan-1 (SDC1; SYND1; CD138) covalently linked to anticancer and/or cytotoxic agents through linkers reported to be useful for the treatment of cancer.

Shanghai Zedeman Pharmaceutical Technology Co. Ltd. has identified aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of autoimmune disease, cancer, diabetes, eye disorders, viral infections, psoriasis, and inflammatory and neurological disorders, among others.

Zeno Management Inc. has divulged GTPase KRAS (mutant) inhibitors (particularly, KRAS (G12C mutant)) reported to be useful for the treatment of cancer.

Aligos Therapeutics Inc. has described programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B.

Beijing Primegene Therapeutics Co. Ltd. has identified azacycloalkane compounds acting as rho kinase 1 (ROCK1; p160-ROCK) and/or rho-associated protein kinase 2 (ROCK 2) inhibitors reported to be useful for the treatment of asthma, cancer, insulin resistance, neurodegeneration, osteoporosis and renal failure.

Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has patented compounds acting as cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

Laekna Therapeutics Shanghai Co. Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Epics Therapeutics SA has described N6-adenosine-methyltransferase catalytic subunit (METTL3) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, infections, and neurological and inflammatory disorders.

Researchers from Allianthera Boston Inc. and Allianthera (Suzhou) Biopharmaceutical Co. Ltd. have prepared and tested serine/arginine-rich protein-specific kinase 1 (SRSF protein kinase 1; SRPK1) inhibitors reported to be useful for the treatment of cancer, inflammation, diabetes, age-related macular degeneration, obesity, arthritis, psoriasis and idiopathic pulmonary fibrosis.

Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified compounds acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.